Floatz logo

N-Butyl Cyanoacrylate

Duodenum Cancer

Minia UniversitySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Duodenum Cancer cohort.

Asset / SponsorPhaseRating
Dalteparin
Asan Medical Center
Phase 2CCC
Apixaban
Asan Medical Center
Phase 2CCC
Kras Tcr-Transduced Pbl
National Cancer Institute (NCI)
Phase 2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Pantoprazole
Washington University School of Medicine
Phase 2CCC
Rivaroxaban
Asan Medical Center
Phase 2CCC
Irinotecan
University of Southern California
Phase 1CC

Same molecule, other indications

N-Butyl Cyanoacrylate is also rated in:

periampullary adenocarcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
bile duct cancerActive
B
Indicative · Phase 3
60 / 100
View asset →
cholangiocarcinomaActive
CCC
Indicative · Phase 3
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →